[1] 吴春晓, 郑莹, 鲍萍萍,等. 上海市胃癌发病流行现况与时间趋势分析[J]. 外科理论与实践, 2008,13(1):24-29. [2] 秦叔逵, 龚新雷. 晚期胃癌化疗的现状和新进展 [J]. 临床肿瘤学杂志, 2006, 11(9):641-652. [3] 李豪侠, 陈晓亮 ,马志敏. 进展期胃癌术前顺铂腹腔内、静脉化疗药代动力学的比较研究[J]. 中国临床药理学与治疗学, 2009, 14(5):126-129. [4] 孙大志, 许玲, 姜林娣,等. 中医药治疗胃癌临床研究文献质量的调查评价 [J].中国临床医学, 2003, 10(6):833-835 [5] The Gastrointestinal Study Group.The concept of locally advanced gastric cancer: effect of treatment on outcome [J]. Cancer, 1990, 66(11):2324-2330. [6] Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase Ⅱ study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma [J]. J Clin Oncol, 2006, 24(33): 5201-5206. [7] Sun S, Li XM, Li XD, et al. Studies on inducing apoptosis effects and mechanism of CIK cells for MGC-803 gastric cancer cell lines [J]. Cancer Biother Radiopharm, 2005, 20(2):173-180. [8] 刘星, 张祥福, 卢辉山,等. 重组改构人肿瘤坏死因子治疗晚期胃癌的随机对照临床研究 [J].中国医药生物技术, 2006, 1(1):46-49. [9] Guo DL, Dong M, Wang L, et al. Expression of gastric cancer-associated MG7 antigen in gastric cancer, precancerous lesions and H. pylori-associated gastric diseases [J]. World J Gastroenterol, 2002, 8(6):1009-1013. [10] 张培彤. 中医肿瘤临床评价标准的探讨 [J]. 中国肿瘤, 1999, 8(10):453. |